Landos Biopharma Company Overview
About Landos Biopharma
Landos Biopharma (NASDAQ:LABP) specializes in the development of innovative oral therapeutics for patients with autoimmune diseases. With a focus on leveraging its proprietary LANCE platform, Landos aims to discover and advance a new wave of medicines targeting the LANCL2, NLRX1, and PLXNA4 pathways. These pathways have shown promise for their potential in managing complex conditions such as Crohn's disease, ulcerative colitis, and other autoimmune diseases, positioning Landos at the forefront of autoimmune therapy research and development. The company's mission revolves around improving patient outcomes and offering new, safer treatment alternatives that can make a significant difference in the lives of those suffering from chronic autoimmune conditions.
Snapshot
Operations
Products and/or services of Landos Biopharma
- Development of an oral immunomodulatory drug, BT-11, targeting the Lanthionine Synthetase C-Like 2 pathway for inflammatory bowel disease.
- Exploration of NX-13, a novel oral therapeutic aiming at the NLRX1 pathway, designed for ulcerative colitis.
- Advancement of LABP-104, an orally active, small molecule for the treatment of systemic lupus erythematosus.
- Investigation into treatments for Crohn's disease, leveraging novel targets within the immune signaling pathways.
- Research into therapies addressing rheumatoid arthritis through the modulation of novel immune pathways.
- Pursuit of novel autoimmune disease treatments through the discovery and development of first-in-class therapeutics.
Landos Biopharma executive team
- Mr. Gregory OakesPresident, CEO & Director
- Dr. Fabio Cataldi M.D.Executive VP & Chief Medical Officer
- Ms. Jennifer CreelInterim Chief Financial Officer
- Ms. Rebecca Mosig Ph.D.Vice President of Corporate Development
- Dr. Josep Bassaganya-Riera DVM, Ph.D.Advisor